GSK Investigational Site

Neo Faliro 18547

0 studies enrolling now · 7 studies all time

What they study most

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Lung Cancer, Non-Small Cell, Neoplasms, Breast, Neoplasms, Head and Neck, Ovarian Neoplasms

Studies at this site

• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer — Completed
• A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients — Stopped early
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer — Completed
• Brain Metastases In ErbB2-Positive Breast Cancer — Stopped early
• Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery — Completed
• An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer — Completed